|
Ten-year risk of death in relation to Recurrence Score and tumor size and grade among ER-positive patients, stratified by treatment with tamoxifen |
||||
| Risk classifier |
Cases |
Controls |
10-Year risk |
|
|
|
||||
| % |
95% CI |
|||
|
|
||||
| Tamoxifen treated |
||||
| Recurrence Score (55 cases and 150 controls) |
||||
| Low (<18) |
29% |
63% |
2.8 |
(1.7–3.9) |
| Intermediate (18–30) |
40% |
23% |
10.7 |
(6.3–14.9) |
| High (≥31) |
31% |
13% |
15.5 |
(7.6–22.8) |
| Tumor size (55 cases and 150 controls) |
||||
| ≤1 cm |
16% |
31% |
3.6 |
(1.7–5.5) |
| 1.1–2 cm |
44% |
43% |
5.8 |
(3.7–7.8) |
| >2 cm |
40% |
26% |
9.3 |
(5.5–13.1) |
| Tumor grade (55 cases and 150 controls) |
||||
| Well |
11% |
33% |
2.1 |
(0.7–3.5) |
| Moderate |
51% |
46% |
6.9 |
(4.7–9.0) |
| Poor |
38% |
21% |
9.9 |
(6.0–13.7) |
| Tumor size and grade (55 cases and 150 controls) |
||||
| ≤2 cm and well or ≤1 cm and moderate |
15% |
43% |
2.5 |
(1.2–3.9) |
| >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor |
49% |
39% |
7.2 |
(4.9–9.5) |
| >2 cm and moderate/poor |
36% |
18% |
11.5 |
(6.6–16.2) |
| Recurrence Score, tumor size and grade |
||||
| Recurrence Score low <18 (16 cases and 95 controls) |
||||
| ≤2 cm and well or ≤1 cm and moderate |
6% |
46% |
0.4 |
(0.0–1.0) |
| >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor |
63% |
39% |
4.1 |
(2.0–6.2) |
| >2 cm and moderate/poor |
31% |
15% |
6.9 |
(1.8–11.7) |
| Recurrence Score intermediate 18–30 (22 cases and 35 controls) |
||||
| ≤2 cm and well or ≤1 cm and moderate |
32% |
51% |
6.8 |
(2.6–10.9) |
| >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor |
45% |
29% |
21.9 |
(5.0–35.8) |
| >2 cm and moderate/poor |
23% |
20% |
13.5 |
(1.2–24.2) |
| Recurrence Score high ≥31 (17 cases and 20 controls) |
||||
| ≤2 cm and well or ≤1 cm and moderate |
0% |
10% |
12.2 |
(0.0–31.0) |
| >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor |
41% |
60% |
10.9 |
(2.9–18.3) |
| >2 cm and moderate/poor |
59% |
30% |
28.9 |
(7.4–45.3) |
| Tamoxifen untreated |
||||
| Recurrence Score (110 cases and 251 controls) |
||||
| Low (<18) |
36% |
64% |
6.2 |
(4.5–7.9) |
| Intermediate (18–30) |
29% |
19% |
17.8 |
(11.8–23.3) |
| High (≥31) |
35% |
18% |
19.9 |
(14.2–25.2) |
| Tumor size (110 cases and 251 controls) |
||||
| ≤1 cm |
29% |
39% |
8.5 |
(6.0–10.9) |
| 1.1–2 cm |
41% |
45% |
10.4 |
(7.8–12.9) |
| >2 cm |
30% |
16% |
16.4 |
(11.4–21.0) |
| Tumor grade (110 cases and 251 controls) |
||||
| Well |
15% |
33% |
5.5 |
(3.4–7.4) |
| Moderate |
49% |
52% |
11.2 |
(8.6–13.8) |
| Poor |
35% |
15% |
22.5 |
(15.9–28.6) |
| Tumor size and grade (110 cases and 251 controls) |
||||
| ≤2 cm and well or ≤1 cm and moderate |
27% |
50% |
6.2 |
(4.3–8.0) |
| >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor |
45% |
37% |
14.2 |
(10.8–17.4) |
| >2 cm and moderate/poor |
27% |
13% |
19.1 |
(13.2–24.7) |
| Recurrence Score, tumor size and grade |
||||
| Recurrence Score low <18 (40 cases and 160 controls) |
||||
| ≤2 cm and well or ≤1 cm and moderate |
35% |
63% |
3.0 |
(1.7–4.3) |
| >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor |
48% |
31% |
11.0 |
(7.0–14.8) |
| >2 cm and moderate/poor |
17% |
6% |
20.2 |
(6.1–32.2) |
| Recurrence Score intermediate 18–30 (32 cases and 47 controls) |
||||
| ≤2 cm and well or ≤1 cm and moderate |
34% |
38% |
17.0 |
(8.2–24.9) |
| >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor |
38% |
34% |
20.9 |
(10.2–30.4) |
| >2 cm and moderate/poor |
28% |
28% |
22.0 |
(9.3–32.9) |
| Recurrence Score high ≥31 (38 cases and 44 controls) |
||||
| ≤2 cm and well or ≤1 cm and moderate |
13% |
14% |
25.0 |
(7.9–39.0) |
| >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor |
50% |
59% |
21.0 |
(13.8–27.5) |
| >2 cm and moderate/poor |
37% |
27% |
25.3 |
(15.1–34.3) |
|
CI, confidence interval; ER, estrogen receptor. | ||||
Habel et al. Breast Cancer Research 2006 8:R25 doi:10.1186/bcr1412 |
||||